XML 20 R10.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Government Grant | 12 Months Ended
--- | ---
Dec. 31, 2021
Receivables [Abstract] |
Government Grant | 4. GOVERNMENT GRANT In July 2021, we were awarded a grant from the National Institute on Drug Abuse, or NIDA, of the National Institutes of Health, or NIH, to evaluate the use of cytisinicline as a treatment for cessation of nicotine e-cigarette use. This initial grant award, in the amount of $0.3 million, commenced on August 1, 2021, and is being utilized to complete critical regulatory and clinical operational activities, such as protocol finalization, clinical trial site identification, drug packaging, and submission of a new Investigational New Drug Application, or IND, to the U.S. Food and Drug Administration, or FDA, for investigating cytisinicline in nicotine e-cigarette users. For the year ended December 31, 2021 we incurred $0.3 million in qualifying R&D expenditures under the NIH grant which has been recorded as a reduction in R&D expense. As of December 31, 2021 we had $0.2 million in grant receivable related to the NIH grant.

X
- Definition Government grants. + References No definition available. + Details
Name: | achv_GovernmentGrantsTextBlock
Namespace Prefix: | achv_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ReceivablesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration